Medical News | Hyperlipidemia

Editor's Choice

Emerging risk factors and risk markers for cardiovascular disease: Looking beyond NCEP ATP III

This review discusses emerging risk factors for CVD, including hs-CRP, lipoprotein(a), homocysteine, fibrinogen, homocysteine, and coronary artery calcification.

LATEST ARTICLES

Second visit of a 47-year-old woman with severe hypertriglyceridemia and type 2 diabetes (CME)

Second visit of a 47-year-old woman with severe hypertriglyceridemia and type 2 diabetes

First visit of a 47-year-old woman with severe hypertriglyceridemia and type 2 diabetes (CME)

First visit of a 47-year-old woman with severe hypertriglyceridemia and type 2 diabetes

Emerging risk factors and risk markers for cardiovascular disease: Looking beyond NCEP ATP III

This review discusses emerging risk factors for CVD, including hs-CRP, lipoprotein(a), homocysteine, fibrinogen, homocysteine, and coronary artery calcification.

Elevated CRP alone doesn't justify statin treatment

C-reactive protein (CRP) doesn't add predictive value to traditional cardiovascular risk factors, and there does not appear to be a causal association between CRP and coronary heart disease (CHD), according to results of two studies published in the July 1, 2009, issue of the Journal of the American Medical Association.

Dose of rosuvastatin daily cuts risk of major CV events

Results from the JUPITER (Justification for the use of statins in primary prevention) trial show that a daily 20 mg dose of rosuvastatin (Crestor) cut participants' risk of a major cardiac event in half, even though these were not patients current guidelines would identify as "at risk."